Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV.

Jason Brophy, Ari Bitnun, Ariane Alimenti, Normand Lapointe, Lindy Samson, Stanley Read, Christos Karatzios, Simon Dobson, Erin Moses, Sandra Blitz, Nancy-Grace Lipsky, Gina Ogilvie, Sharon Walmsley, Janet Raboud, Deborah Money

Pediatric Infectious Disease Journal 2018 June

We evaluated quadrivalent human papillomavirus vaccine seroresponses among 35 girls living with HIV (9-13 years of ages) and compared with data on girls without HIV, as part of a subgroup analysis. The quadrivalent human papillomavirus vaccine was safe and well tolerated. However, antibody response was significantly lower in girls living with HIV relative to girls without HIV. HIV virologic suppression predicted better antibody response.

Full text links

We have located links that may give you full text access.

Show additional links to paperHide additional links to paper

PubMed

Add to Saved Papers

Get 1-tap access

Related Resources

For the best experience, use the Read mobile app

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app